Journal of Neuro-Oncology

, Volume 11, Issue 2, pp 165–170

Primary glial tumor patients treated by combining cis-platin and etoposide

  • A. Boiardi
  • A. Silvani
  • I. Milanesi
  • M. Botturi
  • G. Broggi
Clinical Study

Summary

Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

Key words

chemotherapy glioma cis-platin etoposide survival-time 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dodin P, Sanders C, Georges P and Kenis Y:In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 22: 80–82, 1988Google Scholar
  2. 2.
    Prestayko AW, D'Aqust JC, Iessel BF: Cis-platin. Cancer Treat Rev 6: 17–39, 1979PubMedGoogle Scholar
  3. 3.
    Khan AB, D'Souza BJ, Wharam M, Champion Laa, Sinks LF, Woo SY, McCullough DC, Leventhal BG: Cisplatin in therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013, 1982PubMedGoogle Scholar
  4. 4.
    Bertolone S, Baum E, Krivit W and Hammond D: A phase II study of cisplatin therapy in recurrent childhood brain tumor. J of Neuro-Oncol 7: 5–11, 1989Google Scholar
  5. 5.
    Sexauer CL, Khan A, Burger PC, Krischer JP, Eys J, Vats T, Ragato AH: Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. Cancer 56: 1497–1501, 1985PubMedGoogle Scholar
  6. 6.
    Graig E, Stephen B, Howel B, Felthouse D, Woliver T, Andrews A, Markbamn M and Murphy M: High-dose Cisplatin with sodium Thiosulfate protection. J Clin Oncol 3: 237–244, 1985Google Scholar
  7. 7.
    Feun LG, Lee YY, Wallace S: New drugs and new delivery techniques. Prog Exp Tumor Res 29: 131, 139, 1985PubMedGoogle Scholar
  8. 8.
    Steward DJ, O'Bryan RM, Al-Sarraf M: Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J Neurooncol 1: 145, 147, 1983Google Scholar
  9. 9.
    Einhorn LH and Williams SD: The role of cisplatinum in solid tumor therapy N Engl: J Med 300: 291–294, 1979Google Scholar
  10. 10.
    Burchenal JH, Lokys L: Tumor therapy. In: Prestaiko AW. Cooke ST (ed): Carter SK: Cisplatin: current status and new developments. NY Academic Press 1980Google Scholar
  11. 11.
    Kobayashi T, Yoshida J, Ishiyama J, Noda S, Kito A, Kida Y: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-tumor. J Neurosurg 70: 676–681, 1989PubMedGoogle Scholar
  12. 12.
    Tirelli U, D'Incalci M, Canetta R: Etoposide in malignant brain tumors: A Phase II study: J Clin Oncol 2: 432–437, 1984PubMedGoogle Scholar
  13. 13.
    Steward DJ, Richard MT, Hugenholtz H: Penetration of VP16 into human intracerebral and extracerebral tumors. J Neuro Oncol 2: 133–140, 1984Google Scholar
  14. 14.
    Nelson DF, Schoenfeld D, Weinstein AS: A randomized comparison of misonidazole sensitizer chemotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an EORTC study. Int J Radiat Oncol Biol Phys 9: 1143–1151, 1983PubMedGoogle Scholar
  15. 15.
    Zupi G, Greco C, Sacchi A, Calabresi F: Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapyin vitro andin vivo studies. Eur J Cancer Clin Oncol 12: 1501–1506, 1895Google Scholar
  16. 16.
    Steward DJ, Leavens M, Feun M, Luna M, Bonura J, Caprioloi R, Loo T, Benjamin S: Human central nervous system distribution of cis-platin and use as radiosensitizer in malignant brain tumors. Cumuliforme-results of phase II study. Int J Radiot Oncol Biol Phys 8: 1787–1794, 1982Google Scholar
  17. 17.
    Kornblith P and Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1–17, 1988PubMedGoogle Scholar
  18. 18.
    Edwards MS, Levin VA and Wilson CB: Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980PubMedGoogle Scholar
  19. 19.
    Levin VA, Wilson CB, Davis R, Wara WM, Pischer TR, Irwin L: A phase III comparison of BCNU, hydroxyurea and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51: 526–532, 1979PubMedGoogle Scholar
  20. 20.
    Krauseneck P and Mertens HG: Results of chemotherapy of malignant brain tumors in adults. In therapy of malignant brain tumors. Ed by Kurt Jellinger Springer-Verlag Wien New York 1987Google Scholar
  21. 21.
    Broggi G and Franzini A: Value of serial stereotactic biopsies and impedance monitoring in the treatment of deep brain tumors. J Neurol Neurosurg Psychiatry 44: 397–401, 1981PubMedGoogle Scholar
  22. 22.
    Hoshino T: A commentary on the biology and growth kinetics of low grade and high grade gliomas. J Neurosurg 61: 895–900, 1984PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • A. Boiardi
    • 1
  • A. Silvani
    • 1
  • I. Milanesi
    • 1
  • M. Botturi
    • 3
  • G. Broggi
    • 2
  1. 1.Dept. of NeurologyIstituto Nazionale Neurologico ‘C. Besta’MilanoItaly
  2. 2.Dept. of NeurosurgeryIstituto Nazionale Neurologico ‘C. Besta’MilanoItaly
  3. 3.Dept. of RadiotherapyOspedale di ‘Niguarda’MilanoItaly

Personalised recommendations